

Xbrane Biopharma Q4 2024 - Eventful times

Redeye provides an updated view on Xbrane following its year-end report, which showed continued growth in end-customer sales and signs of improving financials. However, increasing uncertainty in the ranibizumab market leads us to lower our fair value range.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Xbrane Biopharma Q4 2024 - Eventful times](#)